IP Library › Patent Application 14757703
Patent Application
App. No. 14/757,703

Methods and formulations for transdermal administration

Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US None
App. No.
14/757,703
Abstract

Improved formulations for topical treatment that ensure at least localized transdermal or systemic delivery of an active agent through skin, nails or hair follicles are disclosed.

Claims (37)

1 . A formulation for transdermal delivery of an active agent through the skin, nail or hair follicle of a subject, which formulation comprises at least one active agent in an amount effective for treatment of a condition in said subject and

benzyl alcohol—0.5-20% w/w of said formulation; and

lecithin organogel—25-70% w/w of said formulation.

2 . The formulation of claim 1 wherein the lecithin organogel is present at 30%-60% w/w.

3 . The formulation of claim 1 wherein the lecithin organogel is a combination of soy lecithin with isopropyl palmitate.

4 . The formulation of claim 1 which further comprises

nonionic surfactant—2-25% w/w of said formulation; and

polar solvent at least in an amount in molar excess of the nonionic surfactant.

5 . The formulation of claim 4 wherein the polar solvent completes the formulation.

6 . The formulation of claim 4 wherein the nonionic surfactant is a poloxamer and the polar solvent is water.

7 . The formulation of claim 1 which is essentially anhydrous and further comprises nonionic surfactant and bile salt wherein the bile salt is present at 1-15% w/w and the surfactant is provided in powdered form at 20-60% w/w.

8 . The formulation of claim 1 which further contains an antioxidant.

9 . The formulation of claim 1 wherein at least two active agents are included in said formulation.

10 . The formulation of claim 1 wherein the formulation comprises micelles.

11 . The formulation of claim 1 wherein the formulation has a pH of 9-11.

12 . The formulation of claim 1 wherein an active ingredient is an anesthetic, a fat-dissolving agent, a nutrient or nutrient combination, a tissue volume enhancer, a vaccine component, a hair growth modulator, an antifungal agent, an agent to promote smoking cessation, and/or a cannabinoid.

13 . The formulation of claim 1 , which comprises an active agent in an amount effective for treatment of a condition in said subject; and

benzyl alcohol—0.5-20% w/w of said formulation;

lecithin organogel—30-60% w/w of said formulation; and

the remainder of the formulation a 20%-40% w/w nonionic detergent in a polar solvent.

14 . The formulation of claim 1 , which comprises an active agent in an amount effective for treatment of a condition in said subject; and

benzyl alcohol—0.5-20% w/w of said formulation;

lecithin organogel—30-60% w/w of said formulation;

bile salt—5-15% w/w of said formulation; and

the remainder of the formulation a nonionic detergent.

15 . A method to effect transdermal delivery of an active ingredient, which method comprises applying to the skin, nails or hair follicles of a subject an effective amount of the formulation of claim 1 .

16 . A method to dissolve localized fat in a subject which comprises treating the skin proximal to the localized fat with a formulation comprising benzyl alcohol in the range of 0.5% w/w-20% w/w, lecithin organogel in the range of 0.5% w/w-70% w/w, and bile salt in the range of 5-15% w/w.

17 . The method of claim 16 wherein said formulation further comprises an effective amount of anesthetic.

18 . A method to alleviate pain associated with dissolving localized fat in a subject which method comprises, along with said dissolving, applying to the area wherein said dissolving is performed a formulation comprising benzyl alcohol in the range of 0.5% w/w-20% w/w, lecithin organogel in the range of 0.5% w/w-70% w/w and an effective amount of anesthetic.

19 . The method of claim 15 wherein said treating is of skin and which further includes, following said treating, applying a composition comprising linoleic acid to the area of treatment.

20 . The method of claim 16 which further includes, following said treating, applying a composition comprising linoleic acid to the area of treatment.

21 . A penetrant composition which comprises sufficient lecithin organogel, benzyl alcohol, surfactant, polar solvent and/or bile salt to result, when mixed with active agent, the formulation of claim 1 .

22 . A formulation for transdermal delivery of an active agent through the skin, nail or hair follicle of a subject, which formulation comprises at least one active agent in an amount effective for treatment of a condition in said subject and

benzyl alcohol—0.5-20% w/w of said formulation;

lecithin organogel—0.5-70% w/w of said formulation;

bile salt—1-15% w/w of said formulation; and

surfactant—20-60% w/w of said formulation.

Assignments (4)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Dec 19, 2020
From: AMPERSAND BIOPHARMACEUTICALS, INC.
To: DYVE BIOSCIENCES, INC.
Reel/Frame 054702/0547 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Sep 9, 2020
From: BURNHAM, PHILIPPE
To: AMPERSAND BIOPHARMACEUTICALS, INC.
Reel/Frame 053725/0076 →
CHANGE OF NAME Recorded Sep 9, 2020
From: INTELLECTUAL PROPERTY ASSOCIATES, LLC
To: AMPERSAND BIOPHARMACEUTICALS, INC.
Reel/Frame 053738/0169 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Feb 11, 2016
From: SAND, BRUCE J., MD; BEAL, RYAN R.; BURNHAM, PHILIPPE H.
To: INTELLECTUAL PROPERTY ASSOCIATES, LLC
Reel/Frame 037713/0402 →